Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arulatan versus Xalatan in glaucoma or ocular hypertension
RBR-82q4yf5Completed
- Sponsor
- IPEPO
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of latanoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by IPEPO. Started Aug 2018; status: completed.
02
Drugs
latanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on RBR-82q4yf5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-82q4yf5.